Promoting equality and addressing health inequalities are at the heart of NHS England and NHS Improvement’s values. Throughout the development of this guidance we have: given due regard to the need to ...
13-Cisretinoic acid (13-CRA) is a synthetic Vitamin A derivative. High-dose 13-CRA in patients with squamous cell cancers of the head and neck (SCCHN) reduces the incidence of second primary tumors ...
Prophylactic salpingectomy with delayed oophorectomy (PSDO): Feasibility study in women with BRCA mutations. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does ...
Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results